Biotechnology: Pharmaceutical Preparations

Management ChangeAug 13, 2026, 07:10 AM

Olema Pharmaceuticals Appoints Jason O’Byrne as CFO

AI Summary

Olema Pharmaceuticals, Inc. has appointed Jason O’Byrne as its new Chief Financial Officer, effective August 11, 2026. Mr. O'Byrne brings over two decades of finance and global operations leadership from biopharmaceutical companies, including Vir Biotechnology and Caribou Biosciences. His compensation package includes an annual base salary of $545,000, a target annual bonus of 45%, a sign-on bonus totaling $350,000, and an option to purchase 650,000 shares of common stock.

Key Highlights

Jason O’Byrne appointed Chief Financial Officer, effective August 11, 2026.
Mr. O'Byrne previously served as EVP and CFO of Vir Biotechnology from October 2024 to August 2026.
He was CFO of Caribou Biosciences from 2021 to 2024, leading its IPO.
His initial annualized base salary is $545,000.
He is eligible for an annual performance bonus with a target of 45% of his base salary.
He received a sign-on bonus of $250,000 (within 30 days) and $100,000 (after first anniversary).
He will be granted an option to purchase 650,000 shares, vesting over four years.

View SEC Filing

OLMA

Biotechnology: Pharmaceutical Preparations

Olema Pharmaceuticals, Inc.

Price Impact